MASH

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH).

liver
Biotech

Gilead gives up on $15M MASH bet after mulling preclinical data

The U.S. drugmaker “mutually agreed” to terminate its collaboration with South Korean biotech Yuhan for a pair of MASH therapies.
James Waldron Oct 11, 2024 10:28am
proclaim red announcement

Aligos MASH prospect slashes liver fat in phase 2

Sep 19, 2024 1:00pm
arrow back backwards u-turn turn around reverse

Novo Nordisk axes once-monthly GLP-1/GIP agonist MASH prospect

Aug 7, 2024 7:00am
MA strategy deal block push come together form

In struggling Hepion, Israeli biotech spies path to go public

Jul 22, 2024 9:14am
frozen cold viking long boat winter snow

Viking's MASH drug scores where Madrigal's didn't

Jun 4, 2024 1:51pm
reshuffle pipeline target reorganize shift change

Ascletis pulls FXR agonist from pipeline over phase 2 data

Apr 3, 2024 8:50am